A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

计划入组 40 人 · 首次发布于 2017 年 7 月 24 日

Study of BBP-418 in Patients With LGMD2I

计划入组 14 人 · 首次发布于 2021 年 3 月 16 日

A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants

计划入组 112 人 · 首次发布于 2024 年 8 月 15 日

LTG-305

LTG-2950

LTGO-33

CARDINAL HEALTH 418, INC.

United States

Duke Human Vaccine Institute

United States

Ablynx NV

Belgium

Latigo Biotherapeutics Files for IPO as Non-Opioid Pain Drug LTG-001 Advances to Late-Stage Testing

FDA Grants Fast Track Status to Latigo's Novel Non-Opioid Pain Treatment LTG-001

Latigo Bio Doses First Participant in Phase 1 Trial of Non-Opioid Pain Drug LTG-305